<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">665398</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.665398</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Gegen Qinlian Decoction Ameliorates Hyperuricemia-Induced Renal Tubular Injury via Blocking the Inflammatory Signaling Pathway</article-title>
<alt-title alt-title-type="left-running-head">Wang et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">GGQLD Alleviates UA-Induced Renal Injury</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xiao-Jun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Qi</surname>
<given-names>Yi-Ding</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guan</surname>
<given-names>Hao-Chen</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Hua-Gang</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>He</surname>
<given-names>Pei-Qing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guan</surname>
<given-names>Kang-Wei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fu</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ye</surname>
<given-names>Mao-Qing</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/398816/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xiao</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1167906/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Department of Traditional Chinese Medicine, Huadong Hospital Affiliated to Fudan University, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Shanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital Affiliated to Fudan University, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Department of Cardiology, Huadong Hospital Affiliated to Fudan University, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Department of Nephrology, Huadong Hospital Affiliated to Fudan University, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/891169/overview">Yan Xu</ext-link>, Cleveland State University, United&#x20;States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/407989/overview">Kai Xiao</ext-link>, Second Military Medical University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1082558/overview">Xu-Dong Zhou</ext-link>, Hunan University of Chinese Medicine, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Lei Fu, <email>sabrinafl@msn.com</email>; Mao-Qing Ye, <email>yemaoqing@fudan.edu.cn</email>; Jing Xiao, <email>jingxiao13@fudan.edu.cn</email>; Tao Wu, <email>taowuh@hotmail.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>05</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>665398</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>02</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>03</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Wang, Qi, Guan, Lin, He, Guan, Fu, Ye, Xiao and Wu.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Wang, Qi, Guan, Lin, He, Guan, Fu, Ye, Xiao and Wu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Background:</bold> Gegen Qinlian decoction (GGQLD) is a typical traditional Chinese medicine (TCM) prescription documented in <italic>Shang Han Lun</italic>. Clinically, GGQLD has been utilized to manage the inflammatory symptoms of metabolic diseases and to protect against renal damage in China. In the present study, a hypothesis was proposed that the multi-target solution of GGQLD produced anti-inflammatory effects on ameliorating hyperuricemia (HUA).</p>
<p>
<bold>Methods:</bold> A total of 30 primary HUA patients receiving GGQLD treatment (two doses daily) for 4&#xa0;weeks were selected. Then, differences in uric acid (UA) levels and expression of peripheral blood mononuclear cells (PBMCs) and urinary exosomes before and after treatment were analyzed. The therapeutic indexes for the active ingredients in GGQLD against HUA were confirmed through pharmacological subnetwork analysis. Besides, the HUA rat model was established through oral gavage of potassium oxonate and treated with oral GGQLD. In addition, proximal tubular epithelial cells (PTECs) were stimulated by UA and intervened with GGQLD for 48&#xa0;h. Subsequently, RNA-seq, flow cytometry, and confocal immunofluorescence microscopy were further conducted to characterize the differences in UA-mediated inflammation and apoptosis of human renal tubular epithelial cells pre- and post-administration of GGQLD. In the meanwhile, quantitative real-time PCR (qPCR) was carried out to determine gene expression, whereas a western blotting (WB) assay was conducted to measure protein expression.</p>
<p>
<bold>Results:</bold> Our network analysis revealed that GGQLD treated HUA via the anti-inflammatory and antiapoptotic pathways. Additionally, NLPR3 expression significantly decreased in PBMCs and urinary exosomes of HUA patients after GGQLD treatment. <italic>In vivo</italic>, GGQLD treatment alleviated HUA-induced renal inflammation, which was associated with decreased expression of NLRP3 inflammasomes and apoptosis-related mRNAs. Moreover, GGQLD promoted renal UA excretion by inhibiting the activation of GSDMD-dependent pyroptosis induced by NLRP3 inflammasomes and by reducing apoptosis via the mitochondrial apoptosis signaling pathway <italic>in&#x20;vitro</italic>.</p>
<p>
<bold>Conclusion:</bold> This study indicates that GGQLD efficiently reduces inflammatory responses while promoting UA excretion in HUA. Our findings also provide compelling evidence supporting the idea that GGQLD protects against the UA-mediated renal tubular epithelial cell inflammation through the mitochondrial apoptosis signaling pathways. Taken together, these findings have demonstrated a novel therapeutic method for the treatment of&#x20;HUA.</p>
</abstract>
<kwd-group>
<kwd>Gegen Qinlian decoction</kwd>
<kwd>hyperuricemia</kwd>
<kwd>NLRP3</kwd>
<kwd>apoptosis</kwd>
<kwd>pharmacological network analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Hyperuricemia (HUA) is a factor that independently predicts the risk of kidney diseases (<xref ref-type="bibr" rid="B27">Prasad and Qing, 2015</xref>; <xref ref-type="bibr" rid="B32">Srivastava et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B35">Tsai et&#x20;al., 2018</xref>). Generally, HUA is manifested as macrophage infiltration, tubular damage, and upregulated inflammatory mediator levels (<xref ref-type="bibr" rid="B51">Zhou et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B43">Xiao et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B4">Braga et&#x20;al., 2020</xref>). The renal proximal tubule plays a pivotal role in transporting renal urate, which is a major site of urate reabsorption (<xref ref-type="bibr" rid="B20">Lipkowitz, 2012</xref>) and exerts a remarkable role in HUA occurrence and development. In our previous study, soluble uric acid (UA) triggers NLRP3 inflammasome production, IL-1&#x3b2; expression, and caspase-1 activation in human PTECs, which could thus induce the secretion of pro-inflammatory cytokines and activate the innate immunity (<xref ref-type="bibr" rid="B41">Xiao et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B42">Xiao et&#x20;al., 2016</xref>). Therefore, it is of importance to develop a treatment against HUA to prevent renal tubular injury in the future. Till the present, numerous patients have experienced a relapse after the withdrawal of anti-hyperuricemic drugs such as benzbromarone.</p>
<p>For thousands of years, combination therapy has been promoted in traditional Chinese medicine (TCM) to treat different disorders. Among them, Gegen Qinlian decoction (GGQLD), one of the typical TCM prescriptions, was originally documented in the <italic>Treatise on Exogenous Febrile Disease</italic> in the Han Dynasty (202 BC&#x2013;220 CE). GGQLD comprises <italic>Pueraria montana</italic> var. <italic>lobata</italic> (Gegen), <italic>Scutellaria baicalensis Georgi</italic> (Huangqin), <italic>Glycyrrhiza uralensis Fisch. ex DC</italic> (Gancao), and <italic>Coptis chinensis Franch</italic> (Huanglian). It has been extensively utilized for the clinical treatment of gastrointestinal diseases for approximately 2,000&#xa0;years, in particular for damp-heat syndrome&#x2013;related diarrhea (<xref ref-type="bibr" rid="B3">Bi et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B34">Tian et&#x20;al., 2016</xref>). Moreover, the clinical efficacy of GGQLD in treating ulcerative colitis (UC) has been verified (<xref ref-type="bibr" rid="B50">Zhao et&#x20;al., 2020</xref>). Experiments <italic>in&#x20;vitro</italic> and <italic>in vivo</italic> suggest that some active ingredients in GGQLD, like berberine, baicalin, and puerarin, obviously mitigate oxidative stress (OS) and inflammation (<xref ref-type="bibr" rid="B12">Dinesh and Rasool, 2017</xref>; <xref ref-type="bibr" rid="B15">Guarino et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B48">Yu et&#x20;al., 2021</xref>). We previously discovered that GGQLD exerted diabetes-mitigating (<xref ref-type="bibr" rid="B45">Xu et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B19">Li et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B49">Zhang et&#x20;al., 2013</xref>) and anti-inflammation effects through its active ingredients (<xref ref-type="bibr" rid="B33">Tian et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B28">Ryuk et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B40">Wu et&#x20;al., 2019</xref>). Besides, inflammatory response, lipid, and glucose metabolic disorders are also important for HUA. Therefore, guided by the TCM theory of &#x201c;treating different diseases with the same therapy,&#x201d; GGQLD can be sometimes used to treat HUA. However, the underlying mechanism of action has not been clarified.</p>
<p>By network pharmacology, we discovered that GGQLD might treat HUA via the anti-inflammatory and antiapoptotic pathways. Further experiments showed that GGQLD alleviated the inflammatory state of HUA patients and improved renal inflammation in HUA rats. Moreover, <italic>in&#x20;vitro</italic> experiment confirmed that GGQLD played a role in the inflammation and apoptosis of PTECs induced by&#x20;UA.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Materials and Reagents</title>
<p>Cell culture medium and human primary renal PTECs were provided by ScienCell (San Diego, CA, United&#x20;States). Anti-SLC2A9 (URAT1) antibodies, TSG101, CD63, caspase-1, GSDMD, IL-1&#x3b2;, caspase-3, caspase-8, caspase-9, cytochrome c, Bcl-2, and Bax were purchased from ABclonal (Wuhan, China). Oxonic acid (OA) and UA were provided by Sigma (St. Louis, MO, United&#x20;States). CIAS1/NALP3, GAPDH, and anti-GLUT9 were provided by Abcam (Cambridge, United&#x20;Kingdom). In addition, the CCK-8 assay kit was provided by Jiwei Biological Technology (Shanghai, China).</p>
</sec>
<sec id="s2-2">
<title>Preparation of GGQLD</title>
<p>GGQLD, a famous decoction documented in the <italic>Treatise on Exogenous Febrile Disease</italic> around 1,900&#xa0;years ago, was used and approved by the Huadong Hospital Affiliated to Fudan University. The dried herbs, including <italic>Pueraria montana</italic> var. <italic>lobata</italic> (Gegen), <italic>Scutellaria baicalensis Georgi</italic> (Huangqin), <italic>Glycyrrhiza uralensis Fisch. ex DC</italic> (Gancao), and <italic>Coptis chinensis Franch</italic> (Huanglian), in the ratio of 8:3:3:2 (w/w/w/w), were first soaked in distilled water with 15-fold volumes of herbs (v/w) for 30&#xa0;min and then extracted by decoction twice, 2&#xa0;h for the first time and 2&#xa0;h for the second time, with 8-fold volumes of water to herbs (v/w). After filtration, the solution was evaporated under reduced pressure to a suspension with a final density of 1&#xa0;g/ml and stored at 4&#xb0;C for further use (<xref ref-type="bibr" rid="B44">Xie et&#x20;al., 2006</xref>).</p>
</sec>
<sec id="s2-3">
<title>High-Performance Liquid Chromatography (HPLC)</title>
<p>Puerarin, baicalin, liquiritin, and berberine (all purities &#x3e;98%) were provided by Shanghai Yuanzhi Biotechnology Co., Ltd. (Shanghai, China). <xref ref-type="sec" rid="s10">Supplementary Figure S1</xref> presents the chemical structures of the ingredients. Acetonitrile, formic acid, and methanol of HPLC grade were provided by Merck Company (Darmstadt, Germany). The Milli-Q system (Millipore, Milford, MA, United&#x20;States) was utilized to obtain deionized water. Other reagents of analytical grade were acquired from commercial sources. To identify the components of GGQLD, we performed HPLC analysis using an Agilent 1260 Infinity brand chromatographic chain with a C18 chromatographic column (250 &#xd7; 4:6&#xa0;mm, 5&#xa0;&#x3bc;m, Thermo Fisher Scientific, NY, United&#x20;States), along with a column oven, a binary pump, a diode array detector, and an autosampler (Agilent 1100 series). Thereafter, 20&#xa0;ml ethanol extract was added to the column. Throughout the whole chromatographic analysis process, the column injector was maintained at 25&#xb0;C. The mobile phase comprised the ammonium formate solution (10&#xa0;mmol/l, pH 3.0, A) and acetonitrile. For the components, their detection wavelength was set at 270&#xa0;nm. Subsequently, we identified each compound according to the pure standard absorbance spectra and retention time (<xref ref-type="bibr" rid="B16">Guo et&#x20;al., 2019</xref>).</p>
</sec>
<sec id="s2-4">
<title>Systemic Pharmacological Analysis of GGQLD</title>
<p>We searched the active ingredients of Gegen, Huangqin, Huanglian, and Gancao in GGQLD against the TCMSP database (<ext-link ext-link-type="uri" xlink:href="http://tcmspw.com/index.%20ph%20p">http://tcmspw.com/index.php</ext-link>) by the thresholds of druglikeness (DL, also known as the similarity between the known medicines and the components) &#x2265;0.18 and oral bioavailability (OB, medicine component oral availability) &#x2265;30%. Based on the TCMSP database (<xref ref-type="bibr" rid="B46">Yao et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B22">Liu et&#x20;al., 2020</xref>), we aligned the GGQLD active ingredients with the candidate targets separately, then retrieved targets of diverse origins against the UniProt database (<ext-link ext-link-type="uri" xlink:href="http://www.uniport.org">http://www.uniport.org</ext-link>), and acquired the official target gene symbols to perform subsequent assays. A total of 196&#x20;HUA-associated targets were identified from the DisGeNET (<ext-link ext-link-type="uri" xlink:href="http://www.disgenet.org">http://www.disgenet.org</ext-link>) and NCBI databases. Cytoscape 3.8.0 software is the openly accessible bioinformatics platform used to visualize the molecular interaction networks (<xref ref-type="bibr" rid="B10">Deng et&#x20;al., 2020</xref>). In the current study, we adopted Cytoscape to construct the active ingredient&#x2013;target&#x2013;disease&#x2013;medicine interaction network. GO functional annotations and KEGG pathway analyses on the critical therapeutic targets in GGQLD against HUA were analyzed by adopting the DAVID 6.8 database (<xref ref-type="bibr" rid="B17">Komada et&#x20;al., 2018</xref>).</p>
</sec>
<sec id="s2-5">
<title>Participants and Setting</title>
<p>From January 1st, 2020 to October 31st, 2020, a total of 30 male patients with asymptomatic hyperuricemia were enrolled from the Inpatient and Outpatient Departments of the Huadong Hospital Affiliated to Fudan University (Shanghai, China). The patient inclusion criteria are shown below, those aged 18&#x2013;75&#xa0;years with a diagnosis of HUA (serum uric acid, SUA &#x3e; 420&#xa0;&#x3bc;mol/l). For patients receiving anti-HUA treatment, they should receive washout for 2&#xa0;weeks, and we only enrolled patients with SUA &#x3e; 420&#xa0;&#x3bc;mol/l post-washout. The patient exclusion criteria were as follows: 1) those with an allergic physique or previous allergic history to benzbromarone or TCM, 2) serum creatinine &#x3e;1.5&#xa0;mg/dl, 3) two-fold elevation of ALT compared with the normal upper limit, 4) serious stiffness or deformity due to gouty arthropathy, 5) clinically significant arrhythmia, and 6) alcohol abuse history. In addition, patients confirming to any one of the following conditions were also excluded: 1) those having serious concurrent diseases in the hematopoietic system, liver, cerebrovascular system, or kidney, mental diseases, or malignant cancers; 2) those taking salicylate or aspirin (&#x3e;325&#xa0;mg/d)-containing medications; 3) those taking hypouricemic medications, 6-mercaptopurine, or azathioprine; and 4) those who had been involved in additional clinical trials in the last 3&#xa0;months.</p>
<p>In this study, 30 patients were given GGQLD treatment (two doses daily for 4&#xa0;weeks). SUA and urine uric acid (UUA) were adopted for evaluating the therapeutic efficacy (<xref ref-type="table" rid="T1">Table 1</xref>). The Local Ethical Committee of Huadong Hospital Affiliated to Fudan University approved our study protocols (No. 20190037).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Clinical data of HUA patients before and after GGQLD treatment.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left"/>
<th align="center">Before treatment with GGQLD<break/>Mean&#x20;&#xb1; SD</th>
<th align="center">After treatment with GGQLD<break/>Mean&#x20;&#xb1; SD</th>
<th align="center">
<italic>p</italic> value<sup>&#x23;</sup>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">SUA</td>
<td align="char" char="plusmn">497.70&#x20;&#xb1; 39.47</td>
<td align="char" char="plusmn">418.93&#x20;&#xb1; 69.64</td>
<td align="char" char=".">&#x3c;0.001</td>
</tr>
<tr>
<td align="left">UUA</td>
<td align="char" char="plusmn">424.81&#x20;&#xb1; 157.10</td>
<td align="char" char="plusmn">641.62&#x20;&#xb1; 272.83</td>
<td align="char" char=".">0.0128</td>
</tr>
<tr>
<td align="left">Scr</td>
<td align="char" char="plusmn">85.84&#x20;&#xb1; 14.28</td>
<td align="char" char="plusmn">83.88&#x20;&#xb1; 12.34</td>
<td align="char" char=".">0.3699</td>
</tr>
<tr>
<td align="left">BUN</td>
<td align="char" char="plusmn">5.37&#x20;&#xb1; 1.28</td>
<td align="char" char="plusmn">5.84&#x20;&#xb1; 2.42</td>
<td align="char" char=".">0.3518</td>
</tr>
<tr>
<td align="left">eGFR</td>
<td align="char" char="plusmn">85.38&#x20;&#xb1; 17.35</td>
<td align="char" char="plusmn">87.33&#x20;&#xb1; 13.34</td>
<td align="char" char=".">0.4198</td>
</tr>
<tr>
<td align="left">TG</td>
<td align="char" char="plusmn">2.22&#x20;&#xb1; 1.08</td>
<td align="char" char="plusmn">1.81&#x20;&#xb1; 0.69</td>
<td align="char" char=".">0.0263</td>
</tr>
<tr>
<td align="left">TC</td>
<td align="char" char="plusmn">4.59&#x20;&#xb1; 1.04</td>
<td align="char" char="plusmn">4.34&#x20;&#xb1; 0.95</td>
<td align="char" char=".">0.1458</td>
</tr>
<tr>
<td align="left">IL1&#x3b2;</td>
<td align="char" char="plusmn">9.13&#x20;&#xb1; 1.06</td>
<td align="char" char="plusmn">4.67&#x20;&#xb1; 1.15</td>
<td align="char" char=".">0.0005</td>
</tr>
<tr>
<td align="left">IL6</td>
<td align="char" char="plusmn">7.43&#x20;&#xb1; 5.80</td>
<td align="char" char="plusmn">2.35&#x20;&#xb1; 0.70</td>
<td align="char" char=".">0.0389</td>
</tr>
<tr>
<td align="left">IL8</td>
<td align="char" char="plusmn">20.58&#x20;&#xb1; 13.35</td>
<td align="char" char="plusmn">6.40&#x20;&#xb1; 0.77</td>
<td align="char" char=".">0.0206</td>
</tr>
<tr>
<td align="left">ALT</td>
<td align="char" char="plusmn">35.22&#x20;&#xb1; 33.16</td>
<td align="char" char="plusmn">24.96&#x20;&#xb1; 17.38</td>
<td align="char" char=".">0.0380</td>
</tr>
<tr>
<td align="left">AST</td>
<td align="char" char="plusmn">26.46&#x20;&#xb1; 15.28</td>
<td align="char" char="plusmn">20.87&#x20;&#xb1; 9.02</td>
<td align="char" char=".">0.1043</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-6">
<title>Peripheral Blood Mononuclear Cell Isolation by Ficoll-Paque Density Gradient Centrifugation</title>
<p>The Local Ethical Committee of Huadong Hospital Affiliated to Fudan University approved our experimental protocols on human blood (No. 20190037). To be specific, whole blood was centrifuged at 500&#x20;&#xd7; g for 5&#xa0;min at room temperature to separate the plasma. Thereafter, the equivalent amount of 1&#xd7; PBS (under ambient temperature) was used to dilute the rest blood samples, followed by Ficoll-Paque underlaying (under ambient temperature) and 30&#xa0;min of centrifugation (2,000&#xa0;rpm, 21&#xb0;C) using a Heraeus Multifuge X3R (Thermo Fisher Scientific), with the deceleration and acceleration being set at 0 and 5, respectively. Afterward, we obtained PBMCs from the interface between plasma and Ficoll-Paque in the 15&#xa0;ml tube and used 1&#xd7; PBS to wash the cells twice for 10&#xa0;min (1,500&#xa0;rpm, 4&#xb0;C).</p>
</sec>
<sec id="s2-7">
<title>Purification and Characterization of Urine Exosomes and Pellets</title>
<p>We collected urinary exosomes from 8 controls and 8&#x20;GGQLD-intervened HUA patients. Later, 40&#xa0;ml freshly prepared urine samples were collected to obtain urinary cell pellets. Thereafter, the supernatants were subjected to 30&#xa0;min of centrifugation at 12,000 &#xd7; g, followed by standing to isolate the urinary exosomes. ExoQuick-TC for tissue culture media and urine (Exiqon, Woburn, MA, United&#x20;States) was used to isolate urinary exosomes in accordance with specific protocols. To validate the protocols for exosome purification, we performed cryo-transmission electron microscopy to analyze the size, shape, and morphology of urinary exosomes. The isolation of exosomes was characterized by WB using NanoSight.</p>
</sec>
<sec id="s2-8">
<title>Animal Model and Measurement</title>
<p>A total of 15 male SPF SD rats (age, 8&#xa0;weeks; weight, 200&#x2013;250&#xa0;g) were raised at the Animal Center of Shanghai Rat and Mouse Biotech Co., Ltd. Then, all animals were randomized into three groups, including the 1) Cont, 2) OA (8-week administration of OA at 750&#xa0;mg/kg/day), and 3) OA &#x2b; GGQLD (8-week administration of OA at 750&#xa0;mg/kg/day &#x2b; 4-week administration of GGQLD at 10&#xa0;ml/kg/day initiating in week 5) groups, with five in every group. At the end of week 8, each animal was terminated. The 24-h urine was sampled from animals in metabolic cages. Subsequently, the levels of sUA, uUA, serum creatinine (Scr), blood urea nitrogen (BUN), and urinary creatinine (Ucr) were measured through the enzymatic colorimetric assay using a fully automatic chemistry analyzer (MODULAR D/P, Roche). Afterward, the freshly prepared renal cortical samples were obtained immediately after the animals were terminated to measure UA in accordance with specific protocols. Part of the tissues was stained with hematoxylin&#x2013;eosin (HE) or Masson&#x2019;s trichrome stain for light microscopy. Next, the dissected tissue samples were preserved at &#x2212;80&#xb0;C to carry out immunoblotting and RT-PCR assays. Each animal experiment was approved by the Animal Care and Use Committee of Shanghai Rat and Mouse Biotech Co., Ltd. following guidelines of the National Institutes of Health (NIH Pub. No. 85-23, revised 1996).</p>
</sec>
<sec id="s2-9">
<title>Cell Culture</title>
<p>The epithelial cell medium, which was supplemented with basal medium (500&#xa0;ml), fetal bovine serum (10&#xa0;ml, FBS), penicillin/streptomycin (5&#xa0;ml), and epithelial cell growth supplement (5&#xa0;ml), was used to culture human primary PTECs. Then, we incubated cells under 37&#xb0;C and 5% CO<sub>2</sub> conditions. A 24-h &#x201c;growth arrest&#x201d; period was observed within the serum-free medium before stimulation in each experiment.</p>
</sec>
<sec id="s2-10">
<title>Soluble UA Preparation</title>
<p>Previously, we dissolved UA into 1M NaOH to the final concentration of 50&#xa0;mg/ml (<xref ref-type="bibr" rid="B41">Xiao et&#x20;al., 2015</xref>). Then, we examined the solution so as to ensure that there was no mycoplasma and also filtered the solution (pore size, 22&#xa0;&#x3bc;m) prior to use. No detectable crystal was observed under polarizing microscopy or in the process of cell incubation.</p>
</sec>
<sec id="s2-11">
<title>Cell Viability Assay on Cells Treated With Different Doses of GGQLD</title>
<p>A Cell Counting Kit-8 (CCK-8, Beijing Solarbio Science and Technology Co., Ltd.) assay was conducted to assess cell viability after GGQLD treatments at diverse doses. Cells (1 &#xd7; 104 cells/well) were cultivated within the 96-well plate for 24&#x2013;48&#xa0;h. The microplate reader was used to measure absorbance (OD) at 450&#xa0;nm. All experiments were conducted thrice.</p>
</sec>
<sec id="s2-12">
<title>RNA Sequencing</title>
<p>After GGQLD treatment, we harvested PTECs and washed them twice with ice-cold PBS. We collected six samples altogether, among which three were from the GGQLD group while three were from the control group. Trizol reagent (Takara, Dalian, China) was employed to extract total RNA in accordance with specific protocols. Libraries were constructed and mRNA was sequenced by Nuohe Zhiyuan Technology Company (Beijing, China). In addition, DESeq (version 1.30.0) was utilized to identify differentially expressed genes (DEGs). The false discovery rate (FDR) was applied to adjust p value, and the significance thresholds of fold change (FC) &#x2265; 2 and p &#x3c; 0.05 were applied.</p>
</sec>
<sec id="s2-13">
<title>Annexin V-FITC/PI Double-Labeled Flow Cytometry</title>
<p>Flow cytometric analysis was conducted with an Annexin V-FITC apoptosis detection kit (DOJINDO; Kyushu, Japan) to analyze cell apoptosis under specific instructions. After UA and GGQLD treatments, PTECs were harvested and rinsed with ice-cold PBS, followed by staining using the binding buffer that contained Annexin V-FITC/PI at 4&#xb0;C for 15&#xa0;min in the dark. Finally, flow cytometric analysis (Beckman Coulter, Fullerton, CA, United&#x20;States) was performed to record&#x20;cells.</p>
</sec>
<sec id="s2-14">
<title>Confocal Immunofluorescence Microscopy</title>
<p>Cells were cultured onto a laser confocal cell culture dish (Thermo Fisher Scientific, NY, United&#x20;States) in accordance with specific protocols. 24&#xa0;h later, the cells were washed with PBS and fixed by 4% paraformaldehyde in PBS. Thereafter, 10% BSA contained within PBS was utilized to block the cells for 30&#xa0;min, whereas the GSDMD and NLRP3 antibodies in 10% BSA were used to incubate the cells at 4&#xb0;C overnight. Then, the cells were rinsed with PBS thrice and incubated with goat anti-rabbit antibodies (Invitrogen, Grand Island, NY, United&#x20;States) for 1&#xa0;h in the dark. The cells were washed consecutively thrice, and a confocal imaging system (LSM 780;Carl Zeiss, Jena, Germany) was employed to examine the dishes.</p>
</sec>
<sec id="s2-15">
<title>RNA Extraction and Quantitative Real-Time PCR</title>
<p>Trizol (Life Technologies, United&#x20;States) was employed to isolate total cellular and tissue RNA in accordance with specific protocols. The content and purity of RNA were detected through a NanoDrop 2000 (Thermo Fisher Scientific, United&#x20;States). To carry out mRNA quantification, we applied a reverse transcription kit (Vazyme, China) for the reverse transcription of total RNA according to specific instructions. Afterward, SYBR Green Master Mix (Vazyme, China) was utilized to perform qPCR, whereas a Roche Light Cycler system (Roche, Switzerland) was adopted for analysis, with GAPDH being an endogenous control. <xref ref-type="table" rid="T2">Table&#x20;2</xref> lists the primer sequences. Gene expression was normalized to the GAPDH level, which was presented in the manner of FC (2&#x2212;&#x394;&#x394;CT). All results were repeated thrice.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Primers for real-time PCR.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Gene</th>
<th align="center">Forward primer</th>
<th align="center">Reverse primer</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">NLRP3</td>
<td align="left">GCA&#x200b;GCG&#x200b;ATC&#x200b;AAC&#x200b;AGG&#x200b;CGA&#x200b;GAC</td>
<td align="left">TCC&#x200b;CAG&#x200b;CAA&#x200b;ACC&#x200b;TAT&#x200b;CCA&#x200b;CTC&#x200b;CTC</td>
</tr>
<tr>
<td align="left">IL1&#x3b2;</td>
<td align="left">CTC&#x200b;CAC&#x200b;CTC&#x200b;CAG&#x200b;GGA&#x200b;CAG&#x200b;GAT&#x200b;ATG</td>
<td align="left">TCA&#x200b;TCT&#x200b;TTC&#x200b;AAC&#x200b;ACG&#x200b;CAG&#x200b;GAC&#x200b;AGG</td>
</tr>
<tr>
<td align="left">IL18</td>
<td align="left">GCT&#x200b;GCT&#x200b;GAA&#x200b;CCA&#x200b;GTA&#x200b;GAA&#x200b;GAC&#x200b;A</td>
<td align="left">TGC&#x200b;CAA&#x200b;AGT&#x200b;AAT&#x200b;CTG&#x200b;ATT&#x200b;CCA&#x200b;GGT</td>
</tr>
<tr>
<td align="left">TNF</td>
<td align="left">TGG&#x200b;CGT&#x200b;GGA&#x200b;GCT&#x200b;GAG&#x200b;AGA&#x200b;TAA&#x200b;CC</td>
<td align="left">CGA&#x200b;TGC&#x200b;GGC&#x200b;TGA&#x200b;TGG&#x200b;TGT&#x200b;GG</td>
</tr>
<tr>
<td align="left">Bax</td>
<td align="left">GAC&#x200b;GCA&#x200b;TCC&#x200b;ACC&#x200b;AAG&#x200b;AAG&#x200b;CTG&#x200b;AG</td>
<td align="left">GCT&#x200b;GCC&#x200b;ACA&#x200b;CGG&#x200b;AAG&#x200b;AAG&#x200b;ACC</td>
</tr>
<tr>
<td align="left">Bcl2</td>
<td align="left">GGG&#x200b;CTA&#x200b;CGA&#x200b;GTG&#x200b;GGA&#x200b;TAC&#x200b;TGG&#x200b;AG</td>
<td align="left">TCG&#x200b;GTT&#x200b;GCT&#x200b;CTC&#x200b;AGG&#x200b;CTG&#x200b;GAA&#x200b;G</td>
</tr>
<tr>
<td align="left">CYCS</td>
<td align="left">AAA&#x200b;GGG&#x200b;AGG&#x200b;CAA&#x200b;GCA&#x200b;CAA&#x200b;GAC&#x200b;TG</td>
<td align="left">ATT&#x200b;GGC&#x200b;GGC&#x200b;TGT&#x200b;GTA&#x200b;AGA&#x200b;GTA&#x200b;TCC</td>
</tr>
<tr>
<td align="left">CASP8</td>
<td align="left">TCT&#x200b;ACG&#x200b;GAA&#x200b;CGG&#x200b;ATG&#x200b;GGA&#x200b;AGG&#x200b;AAG</td>
<td align="left">CAG&#x200b;GCA&#x200b;CAG&#x200b;GCA&#x200b;CCG&#x200b;CTT&#x200b;TC</td>
</tr>
<tr>
<td align="left">CASP3</td>
<td align="left">GTG&#x200b;GAG&#x200b;GCC&#x200b;GAC&#x200b;TTC&#x200b;TTG&#x200b;TAT&#x200b;GC</td>
<td align="left">TGG&#x200b;CAC&#x200b;AAA&#x200b;GCG&#x200b;ACT&#x200b;GGA&#x200b;TGA&#x200b;AC</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-16">
<title>WB Analysis of the Cultured Human PTECs</title>
<p>Supernatants of cell culture were collected according to the previous description and then the lysis buffer supplemented with protease inhibitor cocktails (Sigma, St Louis, MO, United&#x20;States) was used to lyse the rest cells. After collecting total proteins, we carried out WB analysis according to the previous description (<xref ref-type="bibr" rid="B41">Xiao et&#x20;al., 2015</xref>). In the present work, the following primary antibodies (all were diluted at 1:1,000) were adopted, including rabbit pAb Glut9, rabbit pAb URAT1, rabbit pAb caspase-1, rabbit pAb caspase-3, rabbit pAb NLRP3, rabbit pAb IL-1&#x3b2;, rabbit pAb GSDMD, rabbit pAb Bax, rabbit pAb caspase-8, rabbit pAb cytochrome c, rabbit pAb Bcl-2, and rabbit pAb caspase-9.</p>
</sec>
<sec id="s2-17">
<title>Statistical Analysis</title>
<p>Data were presented in the manner of means&#x20;&#xb1; SD, except as otherwise noted. SPSS19.0 (SPSS, Inc., Chicago, IL, United&#x20;States) was applied for all statistical analyses. For continuous variables, multivariate ANOVA was utilized to assess the differences between the groups. <italic>p</italic>&#x20;&#x3c; 0.05 indicated that a difference was statistically significant. GraphPad Prism 5.0 was employed for drawing&#x20;plots.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Acquisition of Potential Active Ingredients in GGQLD and Common Targets of HUA</title>
<p>A total of 907 ingredients were discovered in GGQLD through the TCMSP database, including 62, 123, 178, and 278 in Gegen, Huangqin, Huanglian, and Gancao, respectively. The thresholds of DL &#x2265; 0.18 and OB &#x2265; 30% were used to screen the active ingredients. Finally, 372 candidate active ingredients conformed to our preset screening thresholds. A total of 196 genes in HUA were screened from the database (DisGeNET). In TCM, a medication displays diverse pharmacological effects via various targets. Therefore, it is greatly significant to determine the TCM medication mechanisms in treating complicated diseases based on network analysis. Previously, we acquired a total of 196 targets for HUA from the DisGeNET database. Then, targets were predicted by incorporating 372 active ingredients in the UniProt database. Consequently, 31 overlapped targets between GGQLD and HUA were obtained by VENN map (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>GO enrichment analysis of the common targets. <bold>(A)</bold> The Venn diagram of both GGQLD targets and HUA targets. <bold>(B)</bold> GO molecular function analysis of overlapping targets. <bold>(C)</bold> GO biological process analysis of overlapping targets. <bold>(D)</bold> GO cellular component analysis of overlapping targets.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Potential Therapeutic Mechanisms of GGQLD in HUA</title>
<p>We performed GO functional annotations of the 31 identified genes, suggesting their involvements in cell components (CCs), biological processes (BPs), and molecular functions (MFs). To be specific, these genes were mainly involved in various BPs, including inflammatory response and negative regulation of the apoptotic process (<xref ref-type="fig" rid="F1">Figures 1B&#x2013;D</xref>). In addition, according to KEGG pathway analysis, the intersected genes were mainly associated with 40 pathways. Among them, 35 pathways with the most significant <italic>p</italic>-values are shown in <xref ref-type="fig" rid="F2">Figure&#x20;2A</xref> including cancers, apoptosis, and inflammatory signaling pathways. In addition, we also constructed the active ingredient&#x2013;target&#x2013;disease network by adopting Cytoscape 3.8.0 software, obtaining the interactions among drugs, compounds, diseases, and targets. The results are shown in <xref ref-type="fig" rid="F3">Figure&#x20;3</xref>. Obviously, 17 targets were related to the apoptosis pathways, 14 to the metabolism pathways, 13 to the inflammation pathways, 13 to the immunity pathways, and 14 to the signal transduction pathways. As illustrated by the VENN map, we acquired 8 intersected targets in the 5 pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). Moreover, the STRING platform was adopted to establish the protein&#x2013;protein interaction (PPI) (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Potential therapeutic mechanisms of GGQLD in hyperuricemia. <bold>(A)</bold> Bubble chart of the top 35 signaling pathways screened by using the KEGG enrichment analysis. <bold>(B)</bold> Venn diagram showing the overlap genes between five types of pathways. <bold>(C)</bold> Protein&#x2013;protein interaction and gene coexpression network.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g002.tif"/>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Drug&#x2013;compound&#x2013;target&#x2013;disease network&#x20;map.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>GGQLD Downregulated the Expression of NLPR3 in PBMCs and Urinary Exosomes in HUA Patients</title>
<p>We found that the SUA and UUA levels (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>) in HUA patients were reduced after GGQLD treatment. Besides, the levels of, IL-6, and IL-8 (<xref ref-type="fig" rid="F4">Figures 4C&#x2013;E</xref>) also significantly decreased in the GGQLD group. According to our previous study, soluble UA induced NLRP3 inflammasome production. To define the possible therapeutic approaches of HUA-induced renal tubular injury, the present study analyzed the expression of NLRP3 in PBMCs and that of urinary exosome protein in HUA patients before and after GGQLD treatment. By isolating PBMCs and extracting urinary exosomes from HUA patients before and after treatment, this study conducted flow cytometry and WB assays to analyze two groups of PBMCs and urinary exosomes. As a result, GGQLD downregulated the expression of NLRP3 in HUA patients (<xref ref-type="fig" rid="F4">Figure&#x20;4F,G,K</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>NLRP3 expression is suppressed in HUA patients after GGQLD treatment. <bold>(A&#x2013;E)</bold> Serum uric acid, 24&#xa0;h urine uric acid, IL-1&#x3b2;, IL-6, and IL-8 were studied before and after medication. <bold>(F)</bold> PBMCs, freshly isolated by Ficoll&#x2013;Paque density gradient centrifugation, were stained with mAbs conjugated with FITC and data acquired by flow cytometry. Cells were gated as shown in Figure. <bold>(G)</bold> The expression of NLRP3 inflammatory protein in PBMCs of HUA patients was significantly reduced after GGQLD treatment. <bold>(H&#x2013;J)</bold> Exosome nanoparticle tracking analysis; Exosomes under electron microscope; the characterization exosomes with related markers. <bold>(K)</bold> The expression of NLRP3 inflammatory protein in urinary exosomes of HUA patients was significantly reduced after GGQLD treatment. For <bold>(K)</bold>, <italic>n</italic>&#x20;&#x3d; 3 independent experiments per group. In all statistical plots, data are expressed as the mean&#x20;&#xb1; SD, &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>HPLC Profiles of GGQLD and Its Fractions</title>
<p>We obtained GGQLD extract through the purification of chromatographic grade methanol, since saponin and flavone were the major bioactive ingredients in GGQLD. Besides, HPLC analysis was performed to investigate the chemical features of GGQLD extract, with methanol being the eluent. To obtain the superb efficiency and favorable separation selectivity of HPLC analysis, we optimized the composition of the mobile phase (10&#xa0;mmol/l acetonitrile&#x2013;water contained within the ammonium formate solution). According to <xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>, the major bioactive ingredient puerarin was identified in Gegen, baicalin in Huangqin, berberine in Huanglian, and liquiritin in Gancao, which were later adopted to construct a combined standard approach. Accordingly, we detected four peaks of GQT extract from the HPLC chromatogram and adopted related chemical standards to quantify levels of puerarin, liquiritin, berberine, and baicalin (Peaks A&#x2013;D), respectively. To be specific, the contents of the above four active ingredients were 3.9, 0.3, 2.9, and 1.0&#xa0;mg/ml in GGQLD extract, respectively (<xref ref-type="table" rid="T3">Table&#x20;3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Contents of the four major compounds in GGQLD.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Sample name</th>
<th align="center">Puerarin (mg/ml)</th>
<th align="center">Liquiritin (mg/ml)</th>
<th align="center">Baicalin (mg/ml)</th>
<th align="center">Berberine (mg/ml)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Sample 1</td>
<td align="char" char=".">3.971</td>
<td align="char" char=".">0.310</td>
<td align="char" char=".">2.970</td>
<td align="char" char=".">1.047</td>
</tr>
<tr>
<td align="left">Sample 2</td>
<td align="char" char=".">3.967</td>
<td align="char" char=".">0.312</td>
<td align="char" char=".">2.983</td>
<td align="char" char=".">1.051</td>
</tr>
<tr>
<td align="left">Sample 3</td>
<td align="char" char=".">3.969</td>
<td align="char" char=".">0.306</td>
<td align="char" char=".">2.967</td>
<td align="char" char=".">1.048</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-5">
<title>GGQLD Alleviated HUA-Induced Renal Tubular Inflammation and Apoptosis <italic>In Vivo</italic>
</title>
<p>Furthermore, the current work verified the protection of GGQLD against HUA in rat models. In brief, gastric OA at 750&#xa0;mg/kg/day was given to male SD rats for eight consecutive weeks. Meanwhile, GGQLD at 10&#xa0;ml/kg/day initiating on week 5 was given for four consecutive weeks. As a result, NLRP3 staining and mRNA expression increased in renal cortical tissues of OA rats (<xref ref-type="fig" rid="F5">Figures 5C,D</xref>). GGQLD reduced the NLRP3 expression in OA-treated rats (<xref ref-type="fig" rid="F5">Figures 5C,D</xref>). GGQLD significantly attenuated the mRNA expression and staining of IL-1&#x3b2; and caspase-3 in renal tissues of UA rats (<xref ref-type="fig" rid="F5">Figures 5C,G,J</xref>). Additionally, it was found that GGQLD significantly alleviated the mRNA expression of TNF, caspase-3, caspase-8, Bax, Bcl-2, and CYCS in renal tissues of HUA rats (<xref ref-type="fig" rid="F5">Figures 5F,H&#x2013;L</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>GGQLD therapy inhibits NLRP3 expression and expression of the apoptosis gene <italic>in vivo</italic>. <bold>(A)</bold> The renal histological injury of three groups was measured by HE staining. <bold>(B)</bold> The renal fibrosis of four groups was determined by Masson trichrome staining. <bold>(C)</bold> Representative immunohistochemical staining images of NLRP3, IL1&#x3b2;, and caspase-3 expression in renal tissue. <italic>N</italic>&#x20;&#x3d; 3 rats/group. Scale bars, 100&#xa0;mm. <bold>(D,E,G)</bold> GGQLD protected the kidney through suppressing the relative mRNA levels of NLRP3 inflammasomes, IL-1&#x3b2;, and IL-18 in HUA rats. <bold>(F,H&#x2013;L)</bold> GGQLD alleviated the relative mRNA levels of apoptosis-related genes caspase-3, caspase-8, and TNF and simultaneously alleviated the mRNA levels of mitochondrial apoptosis-related genes Bax, Bcl-2, and CYCS in HUA rats. For <bold>(D&#x2013;L)</bold>, <italic>n</italic>&#x20;&#x3d; 3 independent experiments per group. In all statistical plots, data are expressed as the mean&#x20;&#xb1; SD, &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>GGQLD Inhibited Mitochondrial Apoptosis and Inflammation of PTECs</title>
<p>According to the CCK-8 results, different doses of GGQLD (20, 15, 10, and 5) were used to treat the UA-induced PTECs (<xref ref-type="sec" rid="s10">Supplementary Figure S2</xref>). Based on our RNA-seq data, GGQLD was found to suppress BPs related to mitochondrial apoptosis and inflammatory response (<xref ref-type="fig" rid="F6">Figures 6A&#x2013;C</xref>). Moreover, GGQLD significantly reduced the expression of NLRP3 and GSDMD compared with UA (<xref ref-type="fig" rid="F6">Figure&#x20;6D</xref>). UA remarkably promoted apoptosis at the early and late stages (<xref ref-type="fig" rid="F6">Figure&#x20;6E</xref>), while GGQLD had the opposite effect (<xref ref-type="fig" rid="F6">Figure&#x20;6E</xref>). Besides, we also investigated the effect of GGQLD on the UA-induced expression of Bcl-2 and caspase gene family proteins in PTECs. Consequently, as further confirmed by WB assays, GGQLD significantly reduced the UA-induced NLRP3 expression (<xref ref-type="fig" rid="F6">Figures&#x20;6F,G</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>GGQLD inhibits mitochondrial apoptosis and inflammation in PTECs. <bold>(A)</bold> Gene expression profile was compared between cells in response to GGQLD treatment, and heat maps were generated based on expression of the significantly changed genes related to inflammatory response and the mitochondrial apoptosis process <bold>(B,C)</bold>. <bold>(D)</bold> GGQLD alleviating inflammasome-induced pyroptosis through inhibiting the NLRP3/GSDMD signal in UA-stimulated PTECs. <bold>(E)</bold> GGQLD alleviated early and late apoptosis. <bold>(F,G)</bold> GGQLD also reduced Bcl-2, Bax, cytochrome c, pro &#x2b; active caspase-3, cleaved caspase-3, caspase-9, and caspase-8 expression in UA-stimulated PTECs. The levels of key proteins of the NLRP3 signaling cascade in PTECs by GGQLD treatment. For <bold>(D&#x2013;G)</bold>, <italic>n</italic>&#x20;&#x3d; 3 independent experiments per group. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs. NC, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs. NC, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs. HUA, &#x23;&#x23;<italic>p</italic>&#x20;&#x3c; 0.01 vs. HUA.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g006.tif"/>
</fig>
</sec>
<sec id="s3-7">
<title>GGQLD Down-Regulated the Expression of Urate Transporter in UA-Stimulated PTECs</title>
<p>UA is mainly regulated by urate transporters. To explore the effect of GGQLD on HUA, this study investigated its effects on URAT1 and GLUT9. As a result, GGQLD significantly downregulated the expression of URAT1 and GLUT9 (<xref ref-type="fig" rid="F7">Figure&#x20;7</xref>) in comparison with the HUA&#x20;group.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>GGQLD alleviated urate transporter expression in UA-stimulated PTECs. GGQLD significantly reduced URAT1 and GLUT9 expressions. <italic>n</italic>&#x20;&#x3d; 3 independent experiments per group. &#x2a;<italic>p</italic>&#x003c;0.05 vs. NC, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs. NC, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs. HUA, &#x23;&#x23;<italic>p</italic>&#x20;&#x3c; 0.01 vs. HUA.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g007.tif"/>
</fig>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>The mechanism of the protective effect of GGQLD in HUA-induced renal injury. The increased UA led to PTEC mitochondrial apoptosis and assembled NLRP3 inflammasomes and facilitated IL-1&#x3b2; maturation and thus inflamed the cells, which damaged the mitochondria and caused pyroptosis to lead to renal tubule damage. GGQLD protected cells from inhibiting the mitochondrial apoptotic pathways through capsase-9, caspase-8, and Bcl-2/Bax/caspase-3, thus alleviating inflammation via inhibition of NLRP3/caspase-1/IL-1&#x3b2;/GSDMD.</p>
</caption>
<graphic xlink:href="fphar-12-665398-g008.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In the present study, clinical data proved that GGQLD reduced the SUA levels and NLRP3 expression in PBMCs and urinary exosomes in asymptomatic HUA patients. In addition, it could also be demonstrated that GGQLD significantly suppressed NLRP3 inflammasome production within the renal cortical tissues in HUA rats and UA-stimulated PTECs. GGQLD significantly prevented the UA-induced renal inflammation, which caused apoptosis via the NLRP3 signaling pathway and the mitochondrial-dependent pathway. The HUA-induced renal injury was significantly alleviated by GGQLD <italic>in&#x20;vitro</italic> and <italic>in&#x20;vivo</italic>.</p>
<p>It is beneficial to inhibit receptors and inflammasomes to reduce renal fibrosis and inflammation. Knocking down Aim2 and NLRP3 can alleviate renal fibrosis, inflammation, and injury (<xref ref-type="bibr" rid="B18">Kopalli et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B5">Cao et&#x20;al., 2021</xref>). In clinical settings, GGQLD has frequently been adopted for the treatment of diabetes and UC (<xref ref-type="bibr" rid="B45">Xu et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B50">Zhao et&#x20;al., 2020</xref>). GGQLD has been suggested to suppress the inflammatory signal transduction pathway and promote the antioxidant effect, thus improving UC. Additionally, GGQLD promotes glucose metabolic disorders, protects pancreatic &#x3b2; cells, and elevates the insulin sensitivity index, thereby exerting an important role in treating diabetes (<xref ref-type="bibr" rid="B2">Ahmed et&#x20;al., 2017</xref>). On this basis, we performed bioinformatics analysis to identify potential therapeutic targets of GGQLD. Our results of the systemic pharmacological analysis proved that the treatment of GGQLD mainly involved the anti-inflammatory and antiapoptotic pathways. In our previous study, NLRP3 was found to be related to the pathogenesis of HUA. Therefore, we hypothesized that GGQLD targeted NLRP3 to exert its anti-inflammatory activity.</p>
<p>NLRP3 is one of the key elements during the activation of inflammation, which can interact with an apoptotic speck-like protein that contains a caspase recruitment domain (CARD) (ASC) through the pyrin domain (PYD). Later, ASC will recruit and activate pro-caspase-1 via CARD. The aforementioned interaction constitutes the NLRP3 inflammasome, which is a kind of great cytosolic protein complex (<xref ref-type="bibr" rid="B6">Csak et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B39">Wree et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B30">Shi et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B1">Abraham et&#x20;al., 2016</xref>). Afterward, the activation of NLRP3 inflammasomes can activate caspase-1. First, caspase-1 cleaves gasdermin D (GSDMD), which can be activated for releasing the active N-terminal protein, and the latter can mediate pyroptosis (<xref ref-type="bibr" rid="B11">Derang&#xe8;re et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B13">Ding et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B29">Sborgi et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B21">Liu et&#x20;al., 2017</xref>). Second, the activation of caspase-1 will recruit and activate the inflammatory molecules like IL-1&#x3b2;, while inducing inflammatory responses. Pyroptosis, also called cellular inflammatory necrosis, can promote the release of cellular contents to activate the inflammatory response (<xref ref-type="bibr" rid="B31">Shi et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B37">Wang et&#x20;al., 2018</xref>). Evidence from previous studies shows that the NLRP3&#x20;inflammasome-induced GSDMD-dependent pyroptosis, accompanied by IL-1&#x3b2; processing, is responsible for renal tubular epithelial cell injury (<xref ref-type="bibr" rid="B23">Miao et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B38">Wang et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B47">Yasukawa and Koshiba, 2021</xref>). In our study, we first compared the difference of NLRP3 expression in PBMCs and urinary exosomes of HUA patients before and after treatment, finding that the expression of NLRP3 significantly decreased after treatment, providing that GGQLD exhibited significant anti-inflammation activity. We further validated and demonstrated that GGQLD significantly reduced the expression of NLRP3, caspase-1, GSDMD, and IL-1&#x3b2; in the UA-stimulated PTEC model <italic>in&#x20;vitro</italic>, suggesting that GGQLD alleviated IL-1&#x3b2; processing and the subsequent amplification of inflammatory cascades. Some scholars have proved that GGQLD exerts an anti-inflammatory effect, and we confirmed that GGQLD showed anti-inflammatory effect by targeting NLRP3-induced GSDMD-dependent pyroptosis in the treatment of&#x20;HUA.</p>
<p>The mitochondrion is an organelle with multiple functions, which is involved in a lot of biological processes, such as energy metabolism and cell suicide (<xref ref-type="bibr" rid="B7">Dagvadorj et&#x20;al., 2021</xref>). It is currently proposed that mitochondrial damage accounts for an important determining factor for the activation of NLRP3 inflammasomes (<xref ref-type="bibr" rid="B25">Mohan et&#x20;al., 2012</xref>). The NLRP3 stimuli&#x2013;induced mitochondrial destruction contributes to exposing mitochondrial DNA (mtDNA) into cytoplasm and generating reactive oxygen species (ROS). The mtDNA in cytoplasm can colocalize with NLRP3, which can thus promote IL-1&#x3b2; release, whereas the oxidized mtDNA can serve as the stronger factor to induce IL-1&#x3b2; secretion. Till the present, mtDNA is only associated with the activation signal related to the responses of NLRP3 inflammasomes. According to the network pharmacology analysis, it is considered that GGQLD exhibited protective effects on uric acid&#x2013;induced renal injury through the apoptotic pathway. Therefore, we speculated that GGQLD may protect HUA-induced renal injury through the antimitochondrial apoptosis pathway.</p>
<p>Proteins in the Bcl-2 family, which include the proapoptotic proteins (like Bad, Bal, and Bax) and the antiapoptotic proteins (like Bcl-2, Mcl-1, and Bcl-xl), are responsible for regulating mitochondrial disruption (<xref ref-type="bibr" rid="B9">Degenhardt et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B36">Vucicevic et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B26">Pe&#xf1;a-Blanco and Garc&#xed;a-S&#xe1;ez, 2018</xref>). Among them, the proapoptotic proteins play the roles of the mitochondrial pathway promoters. After being stimulated, Bak and Bax will be transported in the mitochondrial membrane, which increases the permeability of the mitochondrial outer membrane, causing caspase cascade activation and cytochrome c release (<xref ref-type="bibr" rid="B8">Dairaku et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B14">Fang et&#x20;al., 2012</xref>). In addition, the antiapoptotic proteins play the roles of suppressors through suppressing cytochrome c release (<xref ref-type="bibr" rid="B24">Mo et&#x20;al., 2019</xref>). Bcl-2 is reported to directly reduce mitochondrial membrane permeability through binding to the mitochondrial outer membrane protein voltage-dependent anion channel 1 (VDAC1). Therefore, inducing Bax transport in mitochondria and inhibiting Bcl-2 transport in mitochondria can serve as two approaches for inducing the mitochondria-regulated apoptosis. In our study, we found that GGQLD significantly attenuated the miRNA expression of caspase-3, caspase-8, Bax, Bcl-2, and CYCS in renal tissue from HUA rats. We also examined the effect of GGQLD on the UA-induced expression of Bcl-2 and caspase gene family proteins in PTECs. It can be demonstrated that GGQLD can protect HUA-induced renal epithelial cells by inhibiting mitochondrial apoptosis.</p>
<p>In summary, GGQLD positively affects HUA by suppressing apoptosis and enhancing renal inflammation, which provides laboratory data supporting its clinical application. All the medicinal herbs in GGQLD have been utilized in TCM for thousands of years. Therefore, GGQLD is regarded to be safe and tolerable. GGQLD treatment reduces IL-1&#x3b2; production, NLRP3, caspase-1, and GSDMD expression depending on its concentration. In addition, GGQLD inhibits the apoptosis of PTECs, upregulates the expression of Bcl-2, and downregulates that of Bax, cytochrome c, and caspase-3/8/9. The present work suggests that GGQLD is the best treatment for HUA, which exerts its effects through suppressing apoptosis and renal inflammation. More studies are warranted to examine the systemic molecular mechanisms of GGQLD via the selection of diverse blockers and development of experimental technologies.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The data presented in the study are deposited in the ENA repository, accession number is PRJEB43968.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by The Local Ethical Committee of Huadong Hospital Affiliated to Fudan University (No. 20190037). The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by The Institutional Animal Care and Use Committee (License: SYXK(H)2016-0004).</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>LF, M-QY, and JX conceived and designed the study. X-JW, Y-DQ, H-CG, and H-GL performed the experiments. P-QH and K-WG provided the samples. X-JW wrote the paper. IW, M-QY, and JX reviewed and edited the manuscript. All authors read and approved the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This study was supported by a grant of the Shanghai Municipal Commission of Health and Family Planning Project Grant (No. 2018LQ003).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.665398/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.665398/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Junge</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Drummond</surname>
<given-names>G. S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Translational significance of heme oxygenase in obesity and metabolic syndrome</article-title>. <source>Trends Pharmacol. Sci.</source> <volume>37</volume>, <fpage>17</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2015.09.003</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>S. M. U.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Namani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Nrf2 signaling pathway: pivotal roles in inflammation</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Basis Dis.</source> <volume>1863</volume>, <fpage>585</fpage>&#x2013;<lpage>597</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.11.005</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Prevalence and control of diabetes in Chinese adults</article-title>. <source>JAMA</source> <volume>310</volume>, <fpage>948</fpage>&#x2013;<lpage>959</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.168118</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braga</surname>
<given-names>T. T.</given-names>
</name>
<name>
<surname>Foresto-Neto</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Camara</surname>
<given-names>N. O. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The role of uric acid in inflammasome-mediated kidney injury</article-title>. <source>Curr. Opin. Nephrol. Hypertens.</source> <volume>29</volume>, <fpage>423</fpage>&#x2013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1097/mnh.0000000000000619</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Identification of potential bioactive compounds and mechanisms of GegenQinlian decoction on improving insulin resistance in adipose, liver, and muscle tissue by integrating system pharmacology and bioinformatics analysis</article-title>. <source>J.&#x20;Ethnopharmacol</source> <volume>264</volume>, <fpage>113289</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2020.113289</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csak</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ganz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pespisa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kodys</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dolganiuc</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells</article-title>. <source>Hepatology</source> <volume>54</volume>, <fpage>133</fpage>&#x2013;<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1002/hep.24341</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dagvadorj</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mikulska-Ruminska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tumurkhuu</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Recruitment of pro-IL-1&#x3b1; to mitochondrial cardiolipin, via shared LC3 binding domain, inhibits mitophagy and drives maximal NLRP3 activation</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>1181</volume> (<issue>1</issue>), <fpage>e2015632118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2015632118</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dairaku</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Imatani</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Oligomycin and antimycin A prevent nitric oxide-induced apoptosis by blocking cytochrome C leakage</article-title>. <source>J.&#x20;Lab. Clin. Med.</source> <volume>143</volume> (<issue>3</issue>), <fpage>143</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.lab.2003.11.003</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degenhardt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sundararajan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lindsten</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Bax and Bak independently promote cytochrome cRelease from mitochondria</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>277</volume> (<issue>16</issue>), <fpage>14127</fpage>&#x2013;<lpage>14134</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m109939200</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Network pharmacology identifies the mechanisms of sang-xing-zhi-ke-fang against pharyngitis</article-title>. <source>Evid. Based Complement. Alternat Med.</source> <volume>2020</volume>, <fpage>2421916</fpage>. <pub-id pub-id-type="doi">10.1155/2020/2421916</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derang&#xe8;re</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Chevriaux</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Courtaut</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bruchard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chalmin</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Liver X receptor &#x3b2; activation induces pyroptosis of human and murine colon cancer cells</article-title>. <source>Cell Death Differ</source> <volume>21</volume> (<issue>12</issue>), <fpage>1914</fpage>&#x2013;<lpage>1924</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2014.117</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinesh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rasool</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats</article-title>. <source>Int. Immunopharmacology</source> <volume>44</volume>, <fpage>26</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2016.12.031</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>She</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Pore-forming activity and structural autoinhibition of the gasdermin family</article-title>. <source>Nature</source> <volume>535</volume>, <fpage>111</fpage>&#x2013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1038/nature18590</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>T-2 toxin induces apoptosis in differentiated murine embryonic stem cells through reactive oxygen species-mediated mitochondrial pathway</article-title>. <source>Apoptosis</source> <volume>17</volume> (<issue>8</issue>), <fpage>895</fpage>&#x2013;<lpage>907</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-012-0724-3</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guarino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Strollo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Della Corte</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Letizia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes</article-title>. <source>J.&#x20;Biol. Regul. Homeost Agents</source> <volume>31</volume> (<issue>2</issue>), <fpage>495</fpage>&#x2013;<lpage>502</lpage>. </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Integrating network pharmacology and pharmacological evaluation for deciphering the action mechanism of herbal formula zuojin pill in suppressing hepatocellular carcinoma</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>1185</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.01185</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Platnich</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Benediktsson</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Macrophage uptake of necrotic cell DNA activates the AIM2 inflammasome to regulate a proinflammatory phenotype in CKD</article-title>. <source>Jasn</source> <volume>29</volume>, <fpage>1165</fpage>&#x2013;<lpage>1181</lpage>. <pub-id pub-id-type="doi">10.1681/asn.2017080863</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kopalli</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>T.-B.</given-names>
</name>
<name>
<surname>Koppula</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents</article-title>. <source>Expert Opin. Ther. Patents</source> <volume>26</volume>, <fpage>1239</fpage>&#x2013;<lpage>1256</lpage>. <pub-id pub-id-type="doi">10.1080/13543776.2016.1230201</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X. M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q. L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>[Therapeutic effects of gegen qinlian decoction and its mechanism of action on type 2 diabetic rats]</article-title>. <source>Yao Xue Xue Bao</source>. <volume>48</volume> (<issue>9</issue>), <fpage>1415</fpage>&#x2013;<lpage>1421</lpage>. </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipkowitz</surname>
<given-names>M. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Regulation of uric acid excretion by the kidney</article-title>. <source>Curr. Rheumatol. Rep.</source> <volume>14</volume> (<issue>2</issue>), <fpage>179</fpage>&#x2013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1007/s11926-012-0240-z</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Deciphering the molecular targets and mechanisms of HGWD in the treatment of rheumatoid arthritis via network pharmacology and molecular docking</article-title>. <source>Evid. Based Complement. Alternat Med.</source> <volume>2020</volume>, <fpage>7151634</fpage>. <pub-id pub-id-type="doi">10.1155/2020/7151634</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Melatonin alleviates inflammasome-induced pyroptosis through inhibiting NF-&#x3ba;B/GSDMD signal in mice adipose tissue</article-title>. <source>J.&#x20;Pineal Res.</source> <volume>63</volume> (<issue>1</issue>), <fpage>e12414</fpage>. <pub-id pub-id-type="doi">10.1111/jpi.12414</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The cleavage of gasdermin D by caspase-11 promotes tubular epithelial cell pyroptosis and urinary IL-18 excretion in acute kidney injury</article-title>. <source>Kidney Int.</source> <volume>96</volume> (<issue>5</issue>), <fpage>1105</fpage>&#x2013;<lpage>1120</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2019.04.035</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mo</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.-M.</given-names>
</name>
<name>
<surname>She</surname>
<given-names>C.-S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.-Q.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>C.-G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.-H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Hydrogen-rich saline protects rat from oxygen glucose deprivation and reperusion-induced apoptosis through VDAC1 via Bcl-2</article-title>. <source>Brain Res.</source> <volume>1706</volume> (<issue>1706</issue>), <fpage>110</fpage>&#x2013;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2018.09.037</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abdelwahab</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Kamalidehghan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Syam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>May</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Harmal</surname>
<given-names>N. S. M.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Involvement of NF-&#x3ba;B and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone A</article-title>. <source>Phytomedicine</source> <volume>19</volume> (<issue>11</issue>), <fpage>1007</fpage>&#x2013;<lpage>1015</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2012.05.012</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pe&#xf1;a&#x2010;Blanco</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garc&#xed;a&#x2010;S&#xe1;ez</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Bax, Bak and beyond: mitochondrial performance in apoptosis</article-title>. <source>FEBS J.</source> <volume>285</volume> (<issue>3</issue>), <fpage>416</fpage>&#x2013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1111/febs.14186</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qing</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Associations between hyperuricemia and chronic kidney disease: a review</article-title>. <source>Nephrourol Mon</source> <volume>7</volume> (<issue>3</issue>), <fpage>27233</fpage>. <pub-id pub-id-type="doi">10.5812/numonthly.7(3)2015.27233</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryuk</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Lixia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>B.-S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Efficacy and safety of Gegen Qinlian decoction for normalizing hyperglycemia in diabetic patients: a systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Complement. Therapies Med.</source> <volume>33</volume>, <fpage>6</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctim.2017.05.004</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sborgi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>R&#xfc;hl</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mulvihill</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pipercevic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Heilig</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stahlberg</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death</article-title>. <source>EMBO J.</source> <volume>35</volume>, <fpage>1766</fpage>&#x2013;<lpage>1778</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201694696</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pyroptosis: gasdermin-mediated programmed necrotic cell death</article-title>. <source>Trends Biochem. Sci.</source> <volume>42</volume> (<issue>4</issue>), <fpage>245</fpage>&#x2013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2016.10.004</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title>. <source>Nature</source> <volume>526</volume>, <fpage>660</fpage>&#x2013;<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1038/nature15514</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaze</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>McMullan</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Isakova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Waikar</surname>
<given-names>S. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Uric acid and the risks of kidney failure and death in individuals with CKD</article-title>. <source>Am. J.&#x20;Kidney Dis.</source> <volume>71</volume> (<issue>3</issue>), <fpage>362</fpage>&#x2013;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2017.08.017</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>The efficacy and safety of Chinese herbal decoction in type 2 diabetes: a 5-year retrospective study</article-title>. <source>Evid. Based Complement. Alternat Med.</source> <volume>2016</volume>, <fpage>5473015</fpage>. <pub-id pub-id-type="doi">10.1155/2016/5473015</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>NMR-based metabonomic study of Chinese medicine Gegen Qinlian Decoction as an effective treatment for type 2 diabetes in rats</article-title>. <source>Metabolomics</source> <volume>9</volume> (<issue>6</issue>), <fpage>1228</fpage>&#x2013;<lpage>1242</lpage>. <pub-id pub-id-type="doi">10.1007/s11306-013-0535-8</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>C.-W.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>H.-T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.-C.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>I.-W.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>H.-C.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>C.-C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses</article-title>. <source>Nephrol. Dial. Transpl.</source> <volume>33</volume> (<issue>2</issue>), <fpage>231</fpage>&#x2013;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfx297</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vucicevic</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jakovljevic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Colovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tosic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kostic</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Glumac</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Association of Bax expression and bcl2/bax ratio with clinical and molecular prognostic markers in chronic lymphocytic leukemia</article-title>. <source>J.&#x20;Med. Biochem.</source> <volume>35</volume> (<issue>2</issue>), <fpage>150</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1515/jomb-2015-0017</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>TLR4/NF-&#x3ba;B signaling induces GSDMD-related pyroptosis in tubular cells in diabetic kidney disease</article-title>. <source>Front. Endocrinol.</source> <volume>10</volume>, <fpage>603</fpage>&#x2013;<lpage>611</lpage>. <pub-id pub-id-type="doi">10.3389/fendo.2019.00603</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>GSDME mediates caspase-3-dependent pyroptosis in gastric cancer</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>495</volume> (<issue>1</issue>), <fpage>1418</fpage>&#x2013;<lpage>1425</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2017.11.156</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wree</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McGeough</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Pe&#xf1;a</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Schlattjan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Inzaugarat</surname>
<given-names>M. E.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>NLRP3 inflammasome activation is required for fibrosis development in NAFLD</article-title>. <source>J.&#x20;Mol. Med.</source> <volume>92</volume>, <fpage>1069</fpage>&#x2013;<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-014-1170-1</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice</article-title>. <source>Biomed. Pharmacother.</source> <volume>109</volume>, <fpage>2252</fpage>&#x2013;<lpage>2261</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.11.095</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Uric acid induces TLR4- dependent innate immune response but not HLA-DR and CD40 activation in renal proximal tubular epithelial cells</article-title>. <source>Int. J.&#x20;Clin. Exp. Pathol.</source> <volume>20169</volume>, <fpage>940</fpage>&#x2013;<lpage>949</lpage>. </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-L.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Soluble uric acid increases NALP3 inflammasome and interleukin-1&#x3b2; expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway</article-title>. <source>Int. J.&#x20;Mol. Med.</source> <volume>35</volume>, <fpage>1347</fpage>&#x2013;<lpage>1354</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2015.2148</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Impaired Na&#x2b;&#x2212;K&#x2b;-ATPase signaling in renal proximal tubule contributes to hyperuricemia-induced renal tubular injury</article-title>. <source>Exp. Mol. Med.</source> <volume>50</volume> (<issue>3</issue>), <fpage>e452</fpage>. <pub-id pub-id-type="doi">10.1038/emm.2017.287</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Y.-z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Upton</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Chromatographic fingerprint analysis-a rational approach for quality assessment of traditional Chinese herbal medicine</article-title>. <source>J.&#x20;Chromatogr. A</source> <volume>1112</volume>, <fpage>171</fpage>&#x2013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1016/j.chroma.2005.12.091</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Antidiabetic effects of gegen qinlian decoction via the gut microbiota are attributable to its key ingredient berberine</article-title>. <source>Genomics Proteomics Bioinformatics</source> <volume>17</volume> (<issue>4</issue>), <fpage>249</fpage>&#x2013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.gpb.2019.09.007</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Deciphering the combination principles of Traditional Chinese Medicine from a systems pharmacology perspective based on Ma-huang Decoction</article-title>. <source>J.&#x20;Ethnopharmacology</source> <volume>150</volume> (<issue>2</issue>), <fpage>619</fpage>&#x2013;<lpage>638</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2013.09.018</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasukawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koshiba</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mitochondrial reactive zones in antiviral innate immunity</article-title>. <source>Biochim. Biophys. Acta (Bba) - Gen. Subjects</source> <volume>1865</volume>, <fpage>129839</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2020.129839</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Z.-M.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>X.-M.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.-L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Puerarin induces Nrf2 as a cytoprotective mechanism to prevent cadmium-induced autophagy inhibition and NLRP3 inflammasome activation in AML12 hepatic cells</article-title>. <source>J.&#x20;Inorg. Biochem.</source> <volume>217</volume> (<issue>217</issue>), <fpage>111389</fpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2021.111389</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.-L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>R.-Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.-W.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Anti-diabetic activities of Gegen Qinlian Decoction in high-fat diet combined with streptozotocin-induced diabetic rats and in 3T3-L1 adipocytes</article-title>. <source>Phytomedicine</source> <volume>20</volume>, <fpage>221</fpage>&#x2013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2012.11.002</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Gegen Qinlian decoction maintains colonic mucosal homeostasis in acute/chronic ulcerative colitis via bidirectionally modulating dysregulated Notch signaling</article-title>. <source>Phytomedicine</source> <volume>68</volume>, <fpage>153182</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153182</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway</article-title>. <source>PloS one</source> <volume>7</volume> (<issue>6</issue>), <fpage>e39738</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0039738</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>